CAPItello-281: Updated analysis shows clinically meaningful OS benefit with capivasertib plus abiraterone in patients with PTEN-deficient mHSPC

Genitourinary Cancer

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Ann Oncol

Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ, CAPItello-281 Study Group

doi: 10.1016/j.annonc.2025.10.004

SPECIAL REPORT

Genitourinary Cancer

Sustained OS Benefit with Enzalutamide Plus ADT in mHSPC Including Patients with Cardiometabolic Comorbidities

ESMO 2026

Genitourinary Cancer

PEACE-1: Long-term survival benefit with the addition of abiraterone to SoC in patients with de novo mHSPC

SABCS 2025

Breast Cancer

CAPItello-291: ctDNA analyses confirm benefit of capivasertib plus fulvestrant in HR-positive advanced breast cancer

CHICAGO 2026

Genitourinary Cancer

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC

SABCS 2025

Breast Cancer

NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer

CHICAGO 2026

Genitourinary Cancer

EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma

SABCS 2025

Breast Cancer

Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease

APCCC 2026

Genitourinary Cancer

Related content

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Sustained OS Benefit with Enzalutamide Plus ADT in mHSPC Including Patients with Cardiometabolic Comorbidities

PEACE-1: Long-term survival benefit with the addition of abiraterone to SoC in patients with de novo mHSPC

CAPItello-291: ctDNA analyses confirm benefit of capivasertib plus fulvestrant in HR-positive advanced breast cancer

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC

NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer

EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma

Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease

Triplet Therapy in mHSPC: Patient Selection and Treatment Intensification